| | By Max Bayer Bristol Myers Squibb is closing a 256,000-square-foot research facility in Redwood City, California, as part of the company's larger restructuring. Scientists at the site homed in on studying the tumor microenvironment. |
|
|
|
By Kevin Dunleavy Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment, Beqvez for hemophilia B. It becomes the first FDA-approved gene therapy for Pfizer, which will charge $3.5 million for the single-dose drug. |
By Nick Paul Taylor A $4.9 billion hole has appeared in Gilead’s pipeline. After years of setbacks, the Big Biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline. |
By Zoey Becker As Humira continues its sales free fall, newer Skyrizi is proving a worthy successor with nearly matching sales ahead of an upcoming FDA decision in ulcerative colitis. |
By Fraiser Kansteiner WuXi Biologics has quietly pulled out of the 2024 BIO International Convention in June. The company's withdrawal from the convention comes at a point of heightened tension between Chinese biopharma service providers and certain U.S. lawmakers. |
By Conor Hale At its heart, the 528-page final rule looks to make clear that in vitro diagnostic tests are to be considered medical devices like any other. |
By Gabrielle Masson Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership worth up to $3 billion in biobucks. |
By Angus Liu After a negative phase 3 readout, Gilead Sciences is taking a $2.4 billion impairment charge on the antibody-drug conjugate Trodelvy. With a busy year ahead across therapeutic areas, CEO Dan O'Day emphasized a "time of focused execution." |
By Nick Paul Taylor Pharma’s pandemic-era halo is slipping. After tracking a surge in the industry’s reputation, PatientView found patient groups soured on drugmakers somewhat last year to send pharma’s standing to its lowest level since 2020. |
By Helen Floersh A three-year collaboration between Pfizer and the Research Center for Molecular Medicine of the Austrian Academy of Sciences has resulted in a new AI-driven drug discovery method that could make it faster and easier to identify small molecules with therapeutic potential. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Fierce Healthcare Senior Writer Anastassia Gliadkovskaya dives into the details of the innovation hub being built in New Jersey's SciTech City. |
|
|---|
|
|
Whitepaper Small molecule active pharmaceutical ingredients (APIs) continue to grow more complex. Download the white paper to learn more about using synthesis and route design technology to approach API complexity. Presented by: Lonza |
Whitepaper This paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
eBook To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
Whitepaper Discover the secrets behind successful patient engagement Sponsored by: ProofPilot |
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain. Download this eBook to learn more about the future state of health care dynamics and its affects along the pharmaceutical value chain. Presented by Optum Life Sciences and Advisory Board |
Executive Summary Learn about the current state of biopharma logistics with insights from 150 manufacturers in this exclusive market survey report. Download the report to learn about how regulatory factors and emerging therapies are having an effect on logistics. Sponsored by: Cardinal Health 3PL Services |
eBook Unlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
Whitepaper Clinical trials demand accurate lab data. Central labs uphold standards by ensuring consistency in methodologies, equipment, and reporting. Robust and integrated analytical platforms can support this via real-time access to study and lab data with transparent reporting capabilities, as well as to facilitate critical clinical decision-making and solve drug developers' challenges. Learn more about Preclarus®️ Lab Solutions by PPD®️ from expert Chris Clendening in this paper. Sponsored by: PPD®️ Laboratory Services |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
Whitepaper Selecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. Sponsored by: BioCare |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
